Enobosarm is an oral kind of selective androgen receptor modulator (SARMs) that is in its infancy in the area of research, development and application. It is developed by the pharmaceutical company GTx Inc. in the United States. It is more commonly referred to as Ostarine or Gtx-024. It has currently passed Phase I, II and III trials when tested for its effects on improving lean body mass and physical strength. Because of its relative success in producing results, the US FDA has considered a fast track process for Ostarine. It is still however, not widely available to the public. Ostarine is sold primarily as a research chemical by independent manufacturers. It can even be bought online. Because the full anabolic effects of SARMs has not yet been totally undermined and determined, manufacturers and distributors claim no responsibility for the use and misuse of SARMs. These compounds, despite the promising results of clinical tests, are currently sold as research chemicals only.
Enobosarm is not an illegal substance. In clinical tests, it showed a great potential to cure muscle wasting, osteoporosis and sarcopenia.
Muscle wasting or muscle atrophy is a prevalent condition among cancer, anorexia and AIDS, among the few. It is characterized by the significant loss of large muscle mass within a very short period of time. With this, physical functionality and strength is reduced to the minimum. Muscle wasting occurs when the synthesis of muscle from protein is less than the rate of protein degeneration. Administration of amino acids is the safest and most basic form to address muscle wasting. Next, the use of anabolic steroids for treatment of muscle wasting is preferred among men as this delivers faster results. However, due to the natural of anabolic steroids, the resultant tissue reaction and formation from androgen receptors are not controlled. With the use of anabolic steroids, side effects such as heart problems, bouts of aggression, acne, balding, change in testicular size and virilization and infertility among women are common especially in large dosages for a long time. However the usage of SARMs has been shown to yield very minimal and very limited of the aforementioned side effects.
Muscle wasting is tied to cancer. Patients with non-small cell lung cancer are most at risk of muscle atrophy. Research has estimated that half of the non-small cell lung cancer patients lose 70% of their muscle mass before they die. This translates to a difficulty in climbing stair, kneeling, lifting 10 lbs worth of weight and walking for ¼ miles. Muscle loss in cancer patients is directly correlated with their ability to withstand chemotherapy. As their functions worsen, then so is their chance for tolerating medication. For treatment of cancer-induced muscle loss, 3mg of enobosarm has been tested in clinical trials with 1,200 willing subjects with stage III or IV non-small cell lung cancer for 5 months. The results of this study failed to meet GTx’s set pointers for improved body mass and physical strength. Because of the lack of conclusive data to support its required effects, GTx’s new drug application for Ostarine (NDA) has been postponed.
However, the effects were better than the placebo group so the company is reconsidering to meet with US FDA one more time.
When used in body building, it gives 6 to 10 lbs of lean muscles with an 8-week period at a dosage of 3 mg. Because it is non-toxic to the liver and has no water retention and estrogen rebound effects, it is preferred by men despite the lack of safety trials.
Enobosarm is effective in increasing muscle mass and physical power. It is however banned in sports by the World Anti-Doping Agency, along with other doping substances. Like any doping substances and anabolic steroids, it increases ones stamina and strength. Detection of SARMs in the urine instantly means disqualification from the game.